Introduction
============

Genomic loci linked to human height have been identified by genome‐wide SNP‐association analyses (GWAS) (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon et al. [@b104]). The findings from different studies overlap substantially ([Table 1](#tbl01){ref-type="table"}, Table S1), strongly supporting identification of a significant fraction of height‐determining genes. Cho et al. ([@b13]) performed a corresponding GWAS in a cohort of Korean descent. Notably, fifteen of the genes identified (ACAN, BCAS3 also known as TBX2, EFEMP1, HHIP, HMGA1, HMGA2, LCORL, NCAPG, PLAGL1, PTCH1, SOCS2, SPAG1, UQCC also known as GDF5, ZBTB38, ZNF678) were also identified in the previous studies (Weedon and Frayling [@b102]; Cho et al. [@b13]). Correspondingly, the Caucasian height‐associated genes were confirmed as such in cohorts of Japanese descent (Okada et al. [@b69]). These findings showed that the same genes are largely associated with height in populations of both Caucasian and non‐Caucasian ancestry, and that inherited height‐controlling mechanisms are conserved. Genes close to the SNP most strongly associated with body size were shown to encode extracellular matrix components, proteases, cell cycle controllers, transcription factors and signaling molecules \[(Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon et al. [@b104]) and manuscript in prep.\].

###### 

CpG islands in human height‐associated gene promoters.

  *Genes*                                                                                                    RefSeq number   Chromosome   TSS (nt)    Upstream TSS[^1^](#tf1-1){ref-type="table-fn"}                                                         
  ---------------------------------------------------------------------------------------------------------- --------------- ------------ ----------- ------------------------------------------------ ------ ------- ------ ----------- ----------- ------- ----
  *ACAN* (Weedon et al. [@b104]; Cho et al. [@b13])                                                          NM_013227       15           87147678    1                                                65.7   0.72    1485   87146790    87148274    888     ‡
  *ADAMTSL3* (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon et al. [@b104])                       NM_207517       15           82113842    1                                                68,7   0,82    1974   82113076    82115050    766     ‡
  *ADAMTS17* (Gudbjartsson et al. [@b32])                                                                    NM_139057       15           98699706    2                                                60,7   0,65    888    9908373     9907485     8667    \*
  69,1                                                                                                       0,89            2026         98700323    98698297                                         617    ‡                                              
  *AGPAT6* (Lettre et al. [@b54])                                                                            NM_178819       8            41554876    None                                                                                                   
  *ANAPC13* (Weedon et al. [@b104])                                                                          NM_155391       3            135687519   1                                                59,2   0,788   1548   135688471   135686923   952     ‡
  *ANKS1* (Gudbjartsson et al. [@b32])                                                                       NM_015245       6            34965016    2                                                55     0,80    660    349633552   349634012   1664    
  61,7                                                                                                       0,78            1497         34964519    34966016                                         497    ‡                                              
  *ATAD5* (Gudbjartsson et al. [@b32])                                                                       NM_024857       17           26183149    2                                                62,6   0,78    1368   26175115    26176483    8031    \*
  56,3                                                                                                       0,812           980          26182826    26183806                                         320    ‡                                              
  *ATXN3* (Gudbjartsson et al. [@b32])                                                                       NM_030660       14           91642718    1                                                60,4   0,744   1226   91643223    91641997    516     ‡
  *BCAS3* (Gudbjartsson et al. [@b32]; Cho et al. [@b13])                                                    NM_001099432    17           56109954    2                                                55     0,70    820    56104151    56104971    5803    \*
  59,5                                                                                                       0,65            1058         56109366    56110424                                         588    ‡                                              
  *BMP2* (Gudbjartsson et al. [@b32])                                                                        NM_001200       20           6696745     1                                                66,7   0,95    1988   6695759     6696745     986     ‡
  *BMP6* (Gudbjartsson et al. [@b32])                                                                        NM_001718       6            7672010     1                                                66,8   0,87    2687   7670904     7673591     1106    ‡
  *CABLES1* (Gudbjartsson et al. [@b32])                                                                     NM_001107404    18           18969725    1                                                67,4   0,95    2620   18968684    18971304    1041    ‡
  *CDK6* (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon et al. [@b104])                           NM_001259       7            92301148    2                                                61,2   0,748   2768   92304527    92301759    3379    
  62,1                                                                                                       0,819           1951         92301759    92299808                                         611    ‡                                              
  *CENTA2* (Gudbjartsson et al. [@b32])                                                                      NM_018404       17           26272880    2                                                55,1   0,69    532    26263024    26263556    9856    \*
  65,9                                                                                                       0,74            1687         26272611    26274298                                         269    ‡                                              
  *CHCHD7* (Gudbjartsson et al. [@b32]; Lettre et al. [@b54])                                                NM_024300       8            57286869    1                                                63,7   0,893   1970   57285833    57287803    1036    ‡
  *COIL* (Gudbjartsson et al. [@b32])                                                                        NM_004645       17           52393410    1                                                56,3   0,772   1404   52393685    52392281    275     ‡
  *CPSF2* (Gudbjartsson et al. [@b32])                                                                       NM_175808       13           91658090    1                                                58     0,8     2129   91656710    91658839    1372    ‡
  *CRLF3* (Gudbjartsson et al. [@b32])                                                                       NM_015986       17           26175904    2                                                55,9   0,817   1084   26183907    26182823    8003    \*
  62,6                                                                                                       0,775           1368         26176480    26175112                                         576    ‡                                              
  *DCC* (Lettre et al. [@b54])                                                                               NM_005215       18           48120569    1                                                53,9   0,66    1324   4812170     4813494     399     ‡
  *DEF6* (Gudbjartsson et al. [@b32])                                                                        NM_022047       6            35373573    None                                                                                                   
  *DGKE* (Gudbjartsson et al. [@b32])                                                                        NM_003647       17           52266552    1                                                66,7   0,88    2554   52265265    52267819    1287    ‡
  *DLEU7* (Weedon et al. [@b104])                                                                            NM_198989       13           50315886    1                                                66,4   0,657   1217   50316345    50315128    459     ‡
  *DNM3* (Gudbjartsson et al. [@b32])                                                                        NM_015569       1            170077261   1                                                66,1   0,73    1498   170076559   170078057   702     ‡
  *DNMT3A* (Gudbjartsson et al. [@b32])                                                                      NM_175629       2            25342590    1                                                79,2   0,804   2612   25340227    25342838    248     ‡
  *DOT1L* (Lettre et al. [@b54])                                                                             NM_032482       19           2115148     4                                                55     0,68    505    2108150     21081655    6998    \*
  55                                                                                                         0,75            498          2110214     2110712                                          4934   \*                                             
  56,1                                                                                                       0,65            586          2113068     2113654                                          2080                                                  
  65,3                                                                                                       0,86            2891         2114184     2117075                                          964    ‡                                              
  *DYM* (Weedon et al. [@b104])                                                                              NM_017653       18           45241077    1                                                60,2   0,808   1397   45241580    45240183    503     ‡
  *EFEMP1* (Gudbjartsson et al. [@b32]; Weedon et al. [@b104]; Cho et al. [@b13])                            NM_004105       2            56003860    1                                                58,7   0,683   1350   56004981    56003631    545     ‡
  *E4F1* (Lettre et al. [@b54])                                                                              NM_004424       16           2213568     2                                                64,3   0,92    2647   2204610     2207527     8958    \*
  65,1                                                                                                       0,79            1517         2212727     2214244                                          841    ‡                                              
  *FBLN5* (Gudbjartsson et al. [@b32]; Lettre et al. [@b54])                                                 NM_006329       14           91483799    1                                                57,2   0,77    1357   91484395    91483038    607     ‡
  *FBP2* (Cho et al. [@b13])                                                                                 NM_003837.2     9            97321226    None                                                                                                   
  *FUBP3* (Lettre et al. [@b54])                                                                             NM_003934       9            132444781   1                                                65,2   0,77    1356   132444169   132445525   612     ‡
  *GATAD1* (Gudbjartsson et al. [@b32])                                                                      NM_021167       7            91914701    1                                                60,8   0,80    1442   91914227    91915669    474     ‡
  *GLT25D2* (Gudbjartsson et al. [@b32])                                                                     NM_015101       1            182273486   1                                                65,1   0,771   1841   182273758   182271917   272     ‡
  *GNA12* (Gudbjartsson et al. [@b32])                                                                       NM_007353       7            2850485     1                                                67,2   0,888   1553   2851125     2849572     640     ‡
  *GPR126* (Gudbjartsson et al. [@b32]; Lettre et al. [@b54])                                                NM_001032395    6            142664749   1                                                61,6   0,73    1488   142663983   142665471   776     ‡
  *GRB10* (Lettre et al. [@b54])                                                                             NM_001001549    7            50767544    1                                                67,5   0,965   1964   50829436    50827472    784     ‡
  *HHIP* (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon et al. [@b104]; Cho et al. [@b13])        NM_022475       4            145786623   1                                                62,2   0,70    1869   145785471   145787340   1152    ‡
  *HIST1H1D* (Lettre et al. [@b54])                                                                          NM_005320       6            26343195    1                                                55     0,667   500    26349982    26349482    6787    \*
  *HMGA1* (Gudbjartsson et al. [@b32]; Cho et al. [@b13])                                                    NM_145899       6            34312628    1                                                67,6   0,79    4212   34310234    34314446    2394    ‡
  *HMGA2* (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon et al. [@b104]; Cho et al. [@b13])       NM_003483       12           64504507    1                                                64,4   0,78    3133   64503504    64506637    1003    ‡
  *IHH* (Weedon et al. [@b104])                                                                              NM_002191       2            219633433   1                                                70,2   0,765   1908   219634655   219632747   1222    ‡
  *LBH* (Gudbjartsson et al. [@b32])                                                                         NM_030915       6            30307901    1                                                65,8   0,80    1965   30306777    30308742    1124    ‡
  *LCORL* (Gudbjartsson et al. [@b32]; Weedon et al. [@b104]; Cho et al. [@b13])                             NM_153686       4            17632483    1                                                63,8   0,887   2339   17633555    17631216    1078    ‡
  *LIN28B* (Lettre et al. [@b54])                                                                            NM_001004317    6            105511616   1                                                55,1   0,89    490    105507480   105507970   3986    
  *LTBP1* (Cho et al. [@b13])                                                                                NM_206943.2     2            452207      1                                                65,2   0,909   1292   11650045    11651337    10000   \*
  *LYAR (Lettre* et al. [@b54])                                                                              NM_017816       4            4342744     1                                                61,9   0,69    1379   4343686     4342307     942     ‡
  *LYN* (Gudbjartsson et al. [@b32])                                                                         NM_001111097    8            56954940    1                                                64,9   0,81    1813   56954403    56954926    523     ‡
  *MOS* (Gudbjartsson et al. [@b32])                                                                         NM_022746       8            57189095    2                                                55     0,945   980    57193889    57192909    3994    
  59,9                                                                                                       0,747           1196         57189249    57188053                                         154    ‡                                              
  *MTMR11* (Gudbjartsson et al. [@b32])                                                                      NM_181873       1            148174867   None                                                                                                   
  *NACA2* (Gudbjartsson et al. [@b32])                                                                       NM_199290       17           57023345    None                                                                                                   
  *NCAPG* (Gudbjartsson et al. [@b32]; Cho et al. [@b13])                                                    NM_022346       4            17421623    1                                                59,3   0,89    1574   17420886    17422460    737     ‡
  *NOG* (Gudbjartsson et al. [@b32])                                                                         NM_005450       17           52026059    1                                                64,8   0,79    2982   52024564    52027546    1710    ‡
  *NKX2‐1/TTF1* (Lettre et al. [@b54])                                                                       NM_003317       14           36055353    3                                                60,3   0,67    1661   36064854    36063193    5687    \*
  58,5                                                                                                       0,65            1190         36062574    36061384                                         3407                                                  
  59,4                                                                                                       0,729           2163         36061089    36058926                                         1922   ‡                                              
  *PAPPA* (Lettre et al. [@b54])                                                                             NM_002581       9            117955892   1                                                64,5   0,85    1373   117955869   117957242   23      ‡
  *PENK* (Gudbjartsson et al. [@b32])                                                                        NM_006211       8            57521143    2                                                57,8   0,65    536    57523392    57522856    2249    ‡
  62,2                                                                                                       0,801           2361         57522705    57520344                                         1562   ‡                                              
  *PEX1* (Gudbjartsson et al. [@b32])                                                                        NM_000466       7            91995781    1                                                59,1   0,928   1356   91996364    91995008    583     ‡
  *PLAGL1* (Gudbjartsson et al. [@b32]; Cho et al. [@b13])                                                   NM_002655       8            57286413    1                                                63,7   0,893   1970   57287800    57285830    1408    ‡
  *PNPT1* (Gudbjartsson et al. [@b32])                                                                       NM_033109       2            55774515    1                                                56,1   0,788   909    55774741    55773832    278     ‡
  *PRKG2* (Lettre et al. [@b54])                                                                             NM_006259       4            82345239    1                                                57     0,65    574    82354957    82353513    9718    \*
  *PTCH1* (Weedon et al. [@b104]; Cho et al. [@b13])                                                         NM_001083605    9            97319068    1                                                63,6   0,851   2411   97319965    97317554    897     ‡
  *PXMP3* (Gudbjartsson et al. [@b32])                                                                       NM_001079867    8            78075079    1                                                58,6   0,79    1303   78075931    78074628    852     ‡
  *RAB40C* (Lettre et al. [@b54])                                                                            NM_021168       16           580180      1                                                69,7   0,91    2715   578292      581007      1885    ‡
  *RBBP8* (Gudbjartsson et al. [@b32])                                                                       NM_203291       18           18767837    1                                                58,7   0,90    1476   18766793    18768269    500     ‡
  *RDHE2* (Gudbjartsson et al. [@b32]; Lettre et al. [@b54])                                                 NM_138969       8            57395795    None                                                                                                   
  *RNF135* (Gudbjartsson et al. [@b32])                                                                      NM_197939       17           26322082    1                                                59,2   0,77    1234   26321702    26322936    380     ‡
  *RPS20* (Gudbjartsson et al. [@b32])                                                                       NM_001023       8            57149623    1                                                55,1   0,951   1047   57150084    57149037    461     ‡
  *SCMH1* (Weedon et al. [@b104])                                                                            NM_012236       1            41480375    1                                                68,7   0,798   1999   41481234    41479235    859     ‡
  *SCUBE3* (Gudbjartsson et al. [@b32])                                                                      NM_152753       6            35290168    1                                                63,1   0,77    2003   35288777    35290780    1391    ‡
  *SF3B4* (Gudbjartsson et al. [@b32])                                                                       NM_005850       1            148166326   1                                                56,1   0,651   879    148166783   148165904   457     ‡
  *SH3GL3* (Lettre et al. [@b54])                                                                            NM_003027       15           81907287    1                                                62,6   0,73    1773   81906488    81908261    799     ‡
  *SOCS2* (Gudbjartsson et al. [@b32]; Weedon et al. [@b104]; Cho et al. [@b13])                             NM_003877       12           92487729    1                                                66,4   0,82    2790   92487649    92490439    80      ‡
  *SPAG1* (Weedon et al. [@b104]; Cho et al. [@b13])                                                         NM_003114       8            101239832   1                                                58,1   0,77    1239   101238989   101240228   450     ‡
  *SV2A* (Gudbjartsson et al. [@b32])                                                                        NM_014849       1            148156054   None                                                                                                   
  *TBX2* (Gudbjartsson et al. [@b32])                                                                        NM_005994       17           56832039    1                                                67,3   0,81    5974   56827581    56833555    4458    ‡
  *TBX4* (Gudbjartsson et al. [@b32])                                                                        NM_001003006    17           56888634    3                                                67,1   0,74    1700   56883545    56885245    5044    \*
  62,3                                                                                                       0,81            1298         56886293    56887591                                         2296                                                  
  64,6                                                                                                       0,72            1516         56888304    56889820                                         285    ‡                                              
  *TCP11* (Gudbjartsson et al. [@b32])                                                                       NM_018679       6            35217165    1                                                67,1   0,718   1134   35217617    35216483    452     ‡
  *TGS1* (Gudbjartsson et al. [@b32])                                                                        NM_024831       8            56848345    1                                                59,5   0,8     1400   56847635    56849035    710     ‡
  *TMED3* (Lettre et al. [@b54])                                                                             NM_007364       15           77390546    1                                                66,8   0,71    1133   77389985    77391118    561     ‡
  *TRIM25* (Gudbjartsson et al. [@b32])                                                                      NM_005082       17           52346408    1                                                63,6   0,751   1460   52347061    52345601    653     ‡
  *TRIP11* (Gudbjartsson et al. [@b32]; Lettre et al. [@b54])                                                NM_004239       14           91576570    1                                                56,4   0,768   1310   91576732    91575422    593     ‡
  *UQCC/GDF5* (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon et al. [@b104]; Cho et al. [@b13])   NM_018244       20           33463247    1                                                56,3   0,651   774    33463669    33462895    422     ‡
  *WDR60* (Lettre et al. [@b54])                                                                             NM_01851        7            158342030   1                                                60,7   0,82    1440   158341361   158342801   669     ‡
  *ZBTB38* (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon et al. [@b104]; Cho et al. [@b13])      NM_001080412    3            142525745   None                                                                                                   
  *ZFHX4* (Gudbjartsson et al. [@b32])                                                                       NM_024721       8            77756070    3                                                55     0,78    540    77748585    77749125    7485    \*
  56,6                                                                                                       0,72            1064         77752435    77743499                                         3635                                                  
  55                                                                                                         0,85            545          77755726    77746271                                         344    ‡                                              
  *ZNF76* (Gudbjartsson et al. [@b32])                                                                       NM_003427       6            35335488    1                                                64,5   0,78    1490   35334502    35335992    986     ‡
  *ZNF462* (Gudbjartsson et al. [@b32])                                                                      NM_021224       9            108665199   2                                                55,4   0,72    1475   108661904   108663379   3295    
  61,9                                                                                                       0,65            507          108664296   108664803                                        903                                                   
  *ZNF678* (Weedon et al. [@b104]; Cho et al. [@b13])                                                        NM_178549       1            225817867   1                                                66,4   0,66    1300   225814864   108666164   3003    

TSS: trascription start site. CpG islands were searched for in the region upstream the TSS, within an upper limit of ‐ 10,000 bp.

^‡^CpG islands that overlap the TSS;\*CpG islands in the region −10,000 \< ‐\> −4000 bp upstream the TSS.

Intriguingly, although, up to 90% of the variation in adult height may be explained by genetic factors (Silventoinen et al. [@b89]; Weedon and Frayling [@b102]), stature‐associated polymorphisms have been found to only explain between 2% and 3.7% of height variation (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon and Frayling [@b102]; Weedon et al. [@b104]). More recent analyses have increased the combined predictive power of the identified traits (Yang et al. [@b109]). Nevertheless, a large fraction of heritable height‐associated factors has escaped detection by conventional GWAS (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon and Frayling [@b102]; Weedon et al. [@b104]; Yang et al. [@b109]), consistent with difficulties of previous association studies in finding variants robustly associated with height (Lettre et al. [@b53]; Weedon et al. [@b103]; Sanna et al. [@b82]; Mackay et al. [@b60]).

Notably, rather large cohorts were analyzed in the human height‐SNP association studies (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon et al. [@b104]; Cho et al. [@b13]), which were designed to provide adequate power of detection (approximately 500,000 SNP spaced across the genome (Barrett and Cardon [@b6])). Specific cohorts reached an up to 98% power to detect variants associated with ≥0.5% of the height variation (Lettre et al. [@b54]). The significant overlaps in findings obtained by independent groups (23/87, i.e., 26.4% of the genes, were identified by more than one study) ([Table 1](#tbl01){ref-type="table"}, Table S1), supported the analytical power of the studies performed. In other words, a significant coverage of height‐associated variation appeared to have been reached, and a significant fraction of the most strongly height‐associated loci was actually identified. Nevertheless, a large fraction of heritable height appeared unaccounted for, indicating that a corresponding large fraction of information might have been systematically missed by SNP‐based GWAS. A candidate for such non‐DNA sequence‐linked information is epigenetic heredity. Strategies designed to detect sequence polymorphisms would, indeed, systematically miss genetic information that is not associated with DNA sequence changes.

Functionally‐relevant DNA methylation patterns were thus candidates to be associated with adult stature subgroups in addition to DNA sequence variants. Functionally‐relevant DNA methylation patterns may affect selective mechanisms, thus behaving as true hereditary traits. Consistent with this, a metastable epigenetic heredity of the DWARF1 locus was shown to affect plant size (Miura et al. [@b62]), and this phenotype was inherited through mitosis and meiosis. Notably, environmental conditions, nutrition in particular, have been shown to affect height (Silventoinen et al. [@b88]). DNA methylation patterns can keep record of the nutritional status (El‐Osta et al. [@b25]; Guerrero‐Bosagna et al. [@b34]) and affect, in turn, morphometric parameters (Guerrero‐Bosagna et al. [@b34]). Modifications of DNA methylation patterns in growth‐related genes can be inherited trans‐generationally (Guerrero‐Bosagna et al. [@b34]; Hollingsworth et al. [@b36]; Nadeau [@b64]; Roth et al. [@b78]; Braunschweig et al. [@b11]), through incomplete erasure of epigenetic patterning in the germline. An example of trans‐generational epigenetic heredity of complex traits is that of longevity in *Caenorhabditis elegans* (Greer et al. [@b30]). An accumulation of epigenetic changes through generations would then provide a valuable, reversible mechanism of adaptation to progressively changing environments (Nadeau [@b64]; Roth et al. [@b78]; Verginelli et al. [@b96]).

These findings led us to assess the functional relevance of trait‐associated DNA methylation patterns. Our results indicate that inheritance of CpG island methylation patterns may indeed be involved in the control of body development. They also suggest that environmental influence on height may be mediated by modulation of epigenetic heredity. This may help to account for progressive height changes over multiple generations, through trans‐generational heredity of progressive DNA methylation patterns.

Material and Methods
====================

CpG island ‐ DNA methylation analysis
-------------------------------------

Most genes regulated by DNA methylation contain one or more CpG islands, most frequently in their promoter region (Lander et al. [@b48]; Saxonov et al. [@b83]; Esteller [@b26]; Illingworth and Bird [@b38]; Jin et al. [@b40]). The presence of CpG islands in the 87 genes most strongly associated with the variation in human height (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon et al. [@b104]; Cho et al. [@b13]) was investigated using capabilities of the USC CpG island searcher (cpgislands.usc.edu/) (Takai and Jones [@b92]). The human genome sequence assembly 36.3 was used ([www.ncbi.nlm.nih.gov/sites/entrez](http://www.ncbi.nlm.nih.gov/sites/entrez)). To exclude GC‐rich Alu repetitive elements, CpG island limits of \>500 bp, ≥55% in G + C content and observed CpG/expected CpG \>0.65 were imposed. Validation analyses were performed at the UCSC Genome Browser (genome.ucsc.edu/cgi‐bin/hgGateway) (Illingworth and Bird [@b38]).

Relevance for disease pathological development was investigated using OMIM (Online Mendelian Inheritance in Man) resources ([omim.org](http://omim.org)).

Gene imprinting
---------------

Genomic imprinting is the mechanism by which monoallelic expression is achieved in a parent‐specific fashion. Several human genes are known to be imprinted (Nazor et al. [@b66]). These comprise epigenetic changes, when the imprints are established in the germline, or somatic changes, when they arise during early embryonic development. Genomic imprinting defects are associated with developmental disorders, including Silver‐Russell, Beckwith‐Wiedemann, and Prader‐Willi syndromes. Genomic imprints are affected by environmental factors, and also associate with several human cancers. Gene imprints were then analyzed for paternal or maternal patterns and gene expression regulation ([www.geneimprint.org](http://www.geneimprint.org)).

DNA hypermethylation modules
----------------------------

Association with DNA hypermethylation modules was evaluated as described (Easwaran et al. [@b23]). Briefly, at a genome‐wide level, hypermethylated genes are marked by Polycomb complex signatures. Most of these genes comprise developmental regulators, which contain DNA hypermethylation modules, within bivalent, that is divergently regulated, chromatin.

DNA methylation dynamics
------------------------

The status of DNA methylation of regulatory regions of height‐associated genes was assessed to provide information on DNA methylation dynamics ([www.methdb.de/;202.97.205.78/diseasemeth/](http://www.methdb.de/;202.97.205.78/diseasemeth/)) (Lv et al. [@b59]).

Regulation of height‐associated genes by DNA methylation
--------------------------------------------------------

Mechanistic relevance of DNA methylation was assessed versus a regulatory role of promoter methylation on the expression levels of height‐associated genes.

Signaling networks of height‐associated genes
---------------------------------------------

To detect potential associations to cancer growth control pathways, network‐based analyses were designed:

SNOW (studying networks in the omics world; [babelomics.bioinfo.cipf.es/](http://babelomics.bioinfo.cipf.es/)) builds protein--protein contact networks and maps lists of genes or proteins over a reference interactome, where nodes are proteins and edges are interaction events. A SNOW interactome (*minimal connected networks*, MCN) of height‐associated genes was built using the HPRD (human protein reference database), IntAct, BIND (biomolecular interaction network database), DIP (database of interacting proteins) and MINT (molecular interaction database). Topological parameters included the distributions of node *connections degrees* (i.e., of the number of edges for each node); the *betweenness* (i.e., a measure of centrality of all nodes and of their distribution); the distribution of *clustering coefficients* (i.e., of the connectivity of the neighborhood of each node) and the *number of components* of the network (i.e., the different groups of nodes that are generated in a network analysis). MCNs were identified adopting the option of only one bridging protein between any pair of proteins analyzed. Statistical significance was computed by comparing the obtained networks with the entire reference interactome or with networks of random composition. All networks presented below have significantly higher betweenness and lower connections degrees as compared with irrelevant networks (*P* \< 0.0001) (Fig. [1](#fig01){ref-type="fig"}).

![Pathway analysis. Graphical representation of the height‐associated proteins relationships retrieved through SNOW network analysis. Proteins are represented as nodes (hubs), the biological relationships between the nodes (edges) are represented as lines. Height‐associated proteins are in red; linker proteins are in white; miRNA are in gray. Major hubs are in magenta; SMAD isoforms are in blue.](phy2-2-e12047-g1){#fig01}

MetaCore^™^ network analysis (<http://lsresearch.thomsonreuters.com/pages/solutions/1/metacore>) builds on a curated database. MetaCore^™^ is based on a proprietary manually curated database of human protein‐protein, protein‐DNA and protein‐com pound interactions, metabolic and signaling pathways for human, mouse and rat, supported by proprietary ontologies and controlled vocabulary. Over 2000 multi step canonical pathway maps of human protein‐protein and protein‐DNA interactions are utilized as reference maps. The *analyze network TF* feature was exploited to identify transcriptionally regulated pathways. The *shortest pathway* algorithm was used to link the height‐associated genes with additional database objects along a directed path, enforcing the stringent option of one‐intermediate‐only.

Ingenuity pathways analysis (Ingenuity Systems, [www.ingenuity.com](http://www.ingenuity.com)) was utilized to map height‐associated genes onto the Ingenuity knowledge base (focus points). Networks of focus molecules were generated by maximizing specific connectivities. Networks were ranked by score (negative log *P*‐value by right‐tailed Fisher\'s exact test). Each score takes into account the number of molecules in the network, the final network size, as well as the dataset size and the total number of network‐forming molecules in the Ingenuity Knowledge Base.

Data meta‐analysis (Tables S1--S3) validated identity and relationships between network members ([www.signaling-gateway.org/](http://www.signaling-gateway.org/); [www.wikipathways.org/index.php/Wiki-Pathways](http://www.wikipathways.org/index.php/Wiki-Pathways) and [www.genome.jp/kegg/pathway.html](http://www.genome.jp/kegg/pathway.html)). Yes/no relevance for specific signaling pathways (SMAD; c‐Myc; p53; ER*α*) or processes (development, cell growth; apoptosis) was verified by wet‐lab approaches ([www.ncbi.nlm.nih.gov/sites/entrez](http://www.ncbi.nlm.nih.gov/sites/entrez); and manuscript in prep.).

Statistical analysis
--------------------

Statistical significance of differences between groups was assessed by Fisher exact test (SISA, [www.quantitativeskills.com/sisa/](http://www.quantitativeskills.com/sisa/) and GraphPad Prism 6.02).

Results
=======

DNA methylation of height‐associated genes
------------------------------------------

Most genes regulated by DNA methylation contain one or more CpG islands, most frequently in their promoter region (Lander et al. [@b48]; Saxonov et al. [@b83]; Esteller [@b26]; Illingworth and Bird [@b38]). The presence of CpG islands in the genes most strongly associated with the variation in human height (87 loci) (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon et al. [@b104]; Cho et al. [@b13]) was investigated (Takai and Jones [@b92]) ([Table 1](#tbl01){ref-type="table"}).

Remarkably, 72 of 87 height‐associated genes (82.8%) were found to contain at least one CpG island in the 2,000 bp upstream of the transcription start site (TSS) (99 CpG islands overall) ([Table 1](#tbl01){ref-type="table"}). Notably, in all CpG islands‐associated height genes, CpG islands overlapped with the TSS, supporting an actual regulatory role in gene transcription. As gene expression regulatory regions can significantly extend upstream of the TSS (Koudritsky and Domany [@b46]), we extended our analysis to the 2,000--4,000 bp upstream of the TSS ([Table 1](#tbl01){ref-type="table"}), and identified CpG islands in three additional genes (11 islands overall). More extensive investigation to 10,000 bp 5\' from the TSS identified four additional genes as containing a CpG island (only 15 additional islands overall), suggesting adequate coverage of our search ([Table 1](#tbl01){ref-type="table"} and Table S1). These observed frequencies (90.8% for 10 kb analysis) were strikingly higher than those measured across the whole genome (Jiang et al. [@b39]; Zhu et al. [@b110]). Housekeeping, that is universally expressed, genes contain CpG islands at higher‐than‐average frequency \[78.7% (Larsen et al. [@b51]; Zhu et al. [@b110])\]. Thus, we repeated our analysis after removal of housekeeping height genes \[five cases (Jiang et al. [@b39]; Zhu et al. [@b110])\] ([Table 2](#tbl02){ref-type="table"}). Nonhousekeeping height genes were confirmed to host CpG islands at a much higher‐than‐expected frequency \[87.8% vs. 45% for nonhousekeeping genes (Jiang et al. [@b39])\] (P = 1.10e^−11^; Fisher exact test). It should be noted that most tissue‐specific/nonhousekeeping genes possess neither CpG‐islands nor TATA‐boxes in their core promoters, and only 19.2% of tissue‐specific genes have a TATA‐less CpG‐island associated core promoter (Zhu et al. [@b110]), further supporting the specificity of the association of height genes to CpG islands.

###### 

Functional relevance of DNA methylation of human height‐associated genes.

  Gene symbol     Gene name                                                                    DNA methylation                   Notes[^1^](#tf2-1){ref-type="table-fn"}
  --------------- ---------------------------------------------------------------------------- --------------------------------- -----------------------------------------
  *ACAN*          Aggrecan                                                                                                       
  *ADAMTSL3*      ADAMTS like 3                                                                Dunn et al. ([@b22])              \*
  *ADAMTS17*      ADAM metallopeptidase with thrombospondin type 1 motif 17                    Dunn et al. ([@b22])              \*
  *AGPAT6*        1‐acyglycerol‐3‐phosphate O‐acyltransferase 6                                                                  
  *ANAPC13*       Anaphase promoting complex subunit 13                                                                          
  *ANKS1*         Ankyrin repeat and sterile alpha motif domain containing 1                                                     
  *ATAD5*         ATPase family AAA domain containing 5                                                                          
  *ATXN3*         Ataxin 3                                                                                                       
  *BCAS3*         Breast carcinoma amplified sequence 3                                                                          
  *BMP2*          Bone morphogenic protein 2                                                   Wen et al. ([@b105])              \*
  *BMP6*          Bone morphogenic protein 6                                                   Taniguchi et al. ([@b93])         \*
  *CABLES1*       cdk5 and Abl enzyme substrate 1                                              Sakamoto et al. ([@b81])          \***●**
  *CDK6*          Cyclin‐dependent kinase 6                                                                                      
  *CENTA2*        Centaurin alpha 2                                                                                              
  *CHCHD7*        Coiled‐coil‐helix‐coiled‐coil‐helix domain containing 7                                                        
  *COIL*          Coilin                                                                                                         
  *CPSF2*         Cleavage and polyadenylation specific factor 2                                                                 **●**
  *CRLF3*         Cytokine receptor like factor 3                                                                                
  *DCC*           Deleted in colon carcinoma                                                   Park et al. ([@b72])              \*
  *DEF6*          Differentially expressed in FDCP6 homolog                                                                      
  *DGKE*          Diacylglycerol kinase epsilon 64 kDa                                                                           
  *DLEU7*         Deleted in lymphocytic leukemia                                              Hammarsund et al. ([@b35])        \*
  *DNM3*          Dynamin 3                                                                                                      
  *DNMT3A*        DNA methyl transferase 3 alpha                                               Esteller ([@b26])                 ‡
  *DOT1L*         DOT1‐like,histone H3 methyltransferase                                       Jones et al. ([@b41])             ‡
  *DYM*           Dymeclin                                                                                                       
  *EFEMP1*        EGF containing fibulin like extracellular matrix protein 1                   Sadr‐Nabavi et al. ([@b80])       \*
  *E4F1*          E4F transcription factor 1                                                                                     
  *FBLN5*         Fibulin5                                                                                                       
  *FUBP3*         Far upstream element (FUSE)‐binding protein 3                                                                  
  *GATAD1*        GATA zinc finger domain containing 1                                                                           
  *GLT25D2*       Glycosyltransferase 25 domain containing 2                                                                     
  *GNA12*         Guanine nucleotide‐binding protein (G protein) alpha 12                                                        **●**
  *GPR126*        G protein coupled receptor 126                                                                                 
  *GRB10*         Growth factor receptor bound protein 10                                      Li et al. ([@b56])                \*
  *HHIP*          Hedgehog interacting protein                                                 Tada et al. ([@b91])              \*
  *HIST1H1D*      Histone H1D                                                                  Albig et al. ([@b3])              ‡
  *HMGA1*         High mobility group AT‐hook 1                                                Sgarra et al. ([@b86])            ‡
  *HMGA2*         High mobility group AT‐hook 2                                                Reeves and Beckerbauer ([@b74])   ‡
  *IHH*           Indian hedgehog                                                                                                
  *LBH*           Limb bud and heart development homolog                                                                         
  *LCORL*         Ligand‐dependent nuclear receptor corepressor‐like protein                                                     
  *LIN28B*        Lin 28 homolog B                                                                                               
  *LYAR*          Ly1 antibody reactive homolog                                                                                  
  *LYN*           v‐yes‐1 Yamaguchi sarcoma viral related oncogene homolog                                                       
  *MOS*           v‐mos Moloney murine sarcoma viral oncogene homolog                          Scholz et al. ([@b84])            \*
  *MTMR11*        Myotubularin‐related protein                                                                                   
  *NACA2*         Nascent polypeptide‐associated complex alpha subunit 2                                                         
  *NCAPG*         Non‐SMC condensin I complex subunit G                                                                          
  *NOG*           Noggin                                                                                                         
  *NKX2‐1/TTF1*   NK2 homeobox/thyroid transcription factor 1                                  Kondo et al. ([@b45])             \*
  *PAPPA*         Pregnancy‐associated plasma protein A                                                                          
  *PENK*          Proenkephalin                                                                Comb and Goodman ([@b17])         \*
  *PEX1*          Peroxisome biogenesis factor 1                                                                                 
  *PLAGL1*        Pleomorphic adenoma gene 1                                                   Arima and Wake ([@b5])            \*
  *PNPT1*         Polyribonucleotide nucleotidyltransferase                                                                      
  *PRKG2*         Protein kinase, cGMP‐dependent, type II                                                                        
  *PTCH1*         Patched homolog 1 (hedgehog signaling)                                       Wolf et al. ([@b107])             \*
  *PXMP3*         Peroxisomal membrane protein 3 35 kDa                                                                          **●**
  *RAB40C*        Member RAS oncogene family                                                                                     
  *RBBP8*         Retinoblastoma‐binding protein 8                                             Li et al. ([@b57])                \*
  *RDHE2*         Epidermal dehydrogenase 2                                                                                      
  *RNF135*        Ring finger protein 135                                                                                        
  *RPS20*         Ribosomal protein S20                                                                                          
  *SCMH1*         Sex comb on midleg homolog 1                                                                                   **●**
  *SCUBE3*        Signal peptide CUB‐domain EGF‐like 3                                                                           
  *SF3B4*         Splicing factor 3b subunit 4 49 kDa                                                                            
  *SH3GL3*        SH3‐domain GRB2‐like 3                                                                                         
  *SOCS2*         Suppressor of cytokine signaling 2                                           Sutherland et al. ([@b90])        \*
  *SPAG1*         Sperm antigen 17                                                                                               
  *SV2A*          Synaptic vescicle glycoprotein 2A                                                                              
  *TBX2*          T‐box 2                                                                                                        
  *TBX4*          T‐box 4                                                                                                        
  *TCP11*         t‐complex protein 11                                                                                           
  *TGS1*          Trimethylguanosine synthase homolog                                                                            
  *TMED3*         Transmembrane emp24 protein transport‐domain containing 3                                                      
  *TRIM25*        Tripartite motif containing 25                                                                                 
  *TRIP11*        Thyroid hormone receptor interactor 11                                                                         
  *UQCC/GDF5*     Ubiquinol cytochrome C reductase chaperone/growth differentiation factor 5                                     
  *WDR60*         WD repeat domain 60                                                                                            
  *ZBTB38*        Zinc finger and BTB domain containing 38                                     Filion et al. ([@b27])            ‡
  *ZFHX4*         Zinc finger homeobox 4                                                                                         
  *ZNF76*         Zinc finger protein 76                                                                                         
  *ZNF462*        Zinc finger protein 462                                                                                        
  *ZNF678*        Zinc finger protein 678                                                                                        

\*Genes regulated by DNA methylation; ^‡^Genes regulating DNA methylation; **^●^**Housekeeping genes.

As an internal control, searches for CpG islands were conducted in the transcribed region of height‐associated genes. The regulatory force of CpG islands in transcribed regions is lower than that of islands upstream the TSS (Nguyen et al. [@b67]; Weber et al. [@b101]). Consistently, only 35 height‐associated genes (40.23% of the total) were found to contain CpG islands in transcribed segments (Table S1), which did not exceed the expected frequency. This supported the relevance of a quasi‐universal presence of CpG islands in the promoter of height‐associated genes.

Independent searches for CpG islands were conducted with the UCSC Genome Browser, using broader/less stringent settings \[length of ≥200 bp and for G+C content of ≥50% (Illingworth and Bird [@b38])\] (Table S2). Largely concordant results were obtained with the USC CpG Island Searcher and the UCSC Genome Browser algorithms. The highest concordance was found in the promoter region (84% of the cases), consistent with the actual identification of *bona fide* transcriptionally active CpG islands.

Gene imprinting
---------------

Gene imprinting was analyzed for paternal or maternal patterns and regulation of gene expression ([www.geneimprint.org](http://www.geneimprint.org)). Listed in Table S3 are the height‐associated genes/gene clusters that were found associated with imprinting (Nazor et al. [@b66]). Twenty five height‐associated genes were found to be imprinted. Additionally, imprinting of *GNAS* was shown to lead to either gynogenetic or androgenetic patterns. Growth factor receptor bound protein 10 (*GRB10*) expression was shown an imprinted gene (Li et al. [@b56]). *PLAGL1* lies within a DNA methylation imprinting center on human chromosome region 6q24. Imprinting of *PLAGL1* was also shown by expression and phenotypic profiling of parthenogenetic fetuses (Bischoff et al. [@b9]). Hypomethylation patterns were demonstrated for both *PLAGL1* and *GRB10*. Using Affymetrix GeneChip microarrays (Carletti et al. [@b12]) and/or semiquantitative PCR, organs expression patterns were profiled, and *PLAGL1* was found expressed in a tissue‐specific manner; imprinting was confirmed by pyrosequencing. A paternally imprinted regulatory role was also shown, as paternal noncoding RNAs at this locus can interact with regulators of active chromatin (Iglesias‐Platas et al. [@b37]).

DNA hypermethylation modules
----------------------------

The functional relevance of DNA methylation of height‐associated genes was first assessed by association with DNA hypermethylation modules (Easwaran et al. [@b23]) (Table S3), as marked by Polycomb‐complex signatures within bivalent chromatin. Most of Polycomb‐signed genes comprise developmental regulators, and were shown to contain DNA hypermethylation modules (Easwaran et al. [@b23]). As compared to control H3K4Me3 genes, which are hypermethylated in 1.5% of cases (Easwaran et al. [@b23]), DNA hypermethylation modules were detected in 42/87 height‐associated genes (P = 8.02e^−17^; Fisher exact test, two tailed).

DNA methylation dynamics
------------------------

The extent of DNA methylation of regulatory regions of height‐associated genes was experimentally assessed as described by Lv et al. ([@b59]) ([www.methdb.de/](http://www.methdb.de/); 202.97.205.78/diseasemeth/) (Table S3). All genes where DNA methylation plays a regulatory role are expected to undergo shifts in methylation states. We challenged this prediction in our gene‐set. Only five genes (*ACAN, ANKS1, FBP2, NACA2, ZBTB38*) were found to have no evidence of DNA methylation. The remaining genes (94.3%) were shown to undergo broad changes of DNA methylation levels across experimental conditions (Table S3), consistent with shifting between distinct, DNA methylation‐associated regulatory states.

Regulation of height‐associated genes by DNA methylation
--------------------------------------------------------

A mechanistic relevance of these findings was investigated.

All assessed genes were shown to possess a CpG island in the promoter region that overlaps the TSS (Tables S1, S2), consistent with functional relevance on gene transcription (Esteller [@b26]).

Loss of ADAMTS proteases in nonsmall‐cell lung carcinomas is caused by hypermethylation in the *ADAMTS* genes promoters (Dunn et al. [@b22]).

BMPs are important regulators of cell growth, differentiation, and apoptosis. CpG island methylation in the *BMP2* promoter causes loss of BMP‐2 protein expression in transformed cells (Wen et al. [@b105]). Shut‐down of the *BMP6* gene by promoter methylation was observed in malignant lymphomas (Taniguchi et al. [@b93]).

Cdk5 and Abl enzyme substrate 1 (*CABLES1*) is a cyclin‐dependent kinase binding protein. Loss of nuclear CABLES1 expression is due to epigenetic modifications of the *CABLES1* locus. Full ablation is caused by LOH of the transcriptionally‐competent allele (Sakamoto et al. [@b81]).

The expression of the deleted in colorectal cancer (*DCC*) gene is frequently lost in intestinal cancers. In up to three quarters of the cases the loss of expression of *DCC* is due to DNA methylation (Park et al. [@b72]).

Loss of the deleted in lymphocytic leukemia 7 (*DLEU7*) gene is frequently observed in chronic lymphocytic leukemia, due to hypermethylation of the *DLEU7* promoter (Hammarsund et al. [@b35]).

Decrease or loss of EGF‐containing fibulin‐like extracellular matrix protein 1 (EFEMP1) has been shown in human breast cancer. *EFEMP1* promoter methylation is a major cause of down‐regulation (Sadr‐Nabavi et al. [@b80]).

Hedgehog (Hh) signaling activation is frequently mediated by the epigenetic repression of the Hh‐interacting protein (*HHIP*) gene, a negative regulator of Hh signaling. Consistently, *HHIP* transcription is rescued by demethylation (Tada et al. [@b91]).

Hypermethylation of *MOS* is associated with the development of acute lymphoblastic leukemia (Scholz et al. [@b84]).

CpG methylation inhibits proenkephalin (*PENK*) gene expression by interfering with the binding of the stimulatory transcription factor AP‐2 (Comb and Goodman [@b17]).

Differential methylation of the zinc finger protein gene pleomorphic adenoma gene 1 (*PLAGL1*) was found in diabetes and cancer and was shown to modulate the expression levels of this gene (Arima and Wake [@b5]).

Patched homolog 1 (PTCH1) is the Hh receptor. Methylation of the *PTCH1* promoter inhibits *PTCH1* expression in breast cancers (Wolf et al. [@b107]).

The suppressor of cytokine signaling (*SOCS*) 2 CpG islands are hypermethylated in ovarian cancers. Aberrant methylation of this gene correlates with transcriptional silencing also in hepatocellular carcinomas (Martinez‐Chantar et al. [@b61]).

DNA methylation suppresses the expression of thyroid transcription factor‐1 (TTF‐1) in 60% of undifferentiated thyroid carcinomas (Kondo et al. [@b45]).

c‐Myc is a widely expressed TF, that can bind 10--15% of all genes (Orian et al. [@b70]). c‐Myc regulates at least seven height‐associated genes (*CDK6, COIL, HMGA1, LIN28B, RBBP8, RPS20, TRIM25/EFP*), and its binding to genomic loci is dependent on chromatin structure and CpG methylation.

Epigenetic defects and hereditary growth anomalies
--------------------------------------------------

Distinct epigenetic defects have been linked to separate hereditary growth anomalies, providing evidence for a broad regulatory role of DNA methylation on body growth. The Beckwith‐Wiedemann syndrome (130650) is caused by deregulation of imprinted genes within the 11p15 chromosomal region, i.e., KIP2, H19 and LIT1, whether alone or as interacting regulatory units (Niemitz et al. [@b68]). Hypermethylation at the 11p15 telomeric imprinting control region (ICR1), are observed in about 5 to 10% of affected patients (see below for opposite epigenetic changes in Silver‐Russel patients). Both H19 and LIT1, which encode untranslated RNAs, and IGF2 are either maternally imprinted genes with growth enhancing activity or paternally imprinted genes with growth suppressing activity. Key features of the syndrome are exomphalos, macroglossia, and gigantism in the neonate, supporting a direct involvement of epigenetic regulatory mechanisms in body size and body development. Consistently, alterations include visceromegaly, adrenocortical cytomegaly and overgrowth of the external genitalia in both males and females. Affected children reach an average height of 2.5 SD above the mean at or after puberty, and their growth velocity is above the ninetieth percentile until 4--6 years of age.

Prader--Willi syndrome (176270) is a complex childhood disorder that affects the nervous and hormonal systems and leads to excessive weight gain. It arises from the loss of activity of several imprinted genes on chromosome 15, that are usually expressed from the paternally inherited copy. Affected children suckle poorly for the first months of their lives; their voracious appetite and consequent obesity develop from weaning onwards.

Angelman\'s syndrome (AS) (105830) arises from opposite imprinting defects to those described in Prader--Willi syndrome. The Angelman syndrome is characterized by mental retardation, movement disorders, altered behavior, and speech abnormalities. Most cases are caused by absence of a maternal contribution to the imprinted region on chromosome 15q11‐q13, whereas the Prader‐Willi syndrome results from deletion of the same region in the paternal chromosome. Other patients with an Angelman syndrome carry mutations in the gene encoding methyl‐CpG‐binding protein‐2 (MECP2).

MECP2 (300005) is the gene mutated in the Rett syndrome, a neurological (regression of acquired skills, loss of speech, stereotypical movements, seizures, and mental retardation) and developmental disorder that occurs in females. Notably, affected girls are characterized by microcephaly and arrested development between 6 and 18 months of age.

Imprinting defects are associated with other developmental disorders, for example Silver‐Russell dwarfism. Up to 60% of cases of Silver‐Russell syndrome are caused by hypomethylation at the ICR1 on chromosome 11p15, involving the H19 (103280) and IGF2 (147470) genes (Penaherrera et al. [@b73]). Affected patients demonstrate severe intrauterine growth retardation, poor postnatal growth, craniofacial alterations, and a variety of minor malformations.

Epigenetic regulation of body size
----------------------------------

The findings on Beckwith‐Wiedemann syndrome, Prader--Willi syndrome, Angelman\'s syndrome, Rett syndrome and Silver‐Russell syndrome suggest an epigenetic regulation of body size. Consistently, several other imprinting disorders have been shown to affect placental and fetal size (Constancia et al. [@b18]). The connection between imprinting and placentation is supported by the finding that erasing all genomic imprints results in the outgrowth of extra‐embryonic tissues and placenta in animal models. Correspondingly, imprinting defects in the female human germline cause the appearance of hydatidiform moles, that is uncontrolled growth of placental cells.

Height‐associated regulators of epigenetic heredity
---------------------------------------------------

Height‐associated genes include several key epigenetic regulators of gene expression (Esteller [@b26]). The activity of transcription factors is modulated by associations with co‐repressors, including histone deacetylase 7. BMP2 regulates the transcriptional activity of HDAC7 by inducing its export from the nucleus. The zinc finger and BTB domain containing (ZBTB38) is a methyl‐DNA‐binding transcriptional repressor gene that binds single methylated CpGs. Chromatin immunoprecipitation indicates that ZBTB38 recognizes the methylated alleles of the H19 and insulin‐like growth factor II (IGF‐2) genes and represses their transcription (Filion et al. [@b27]). Methylation‐linked inactivation of IGF‐2/H19 can be inherited in a parental‐specific manner (Riccio et al. [@b75]).

The DOT1‐like and NSD1 histone methyltransferases, the two high‐mobility group A (HMGA) genes, HMGA1 and HMGA2, and the histone clusters 1 and 2 are all involved in the assembly of chromatin structure. Notably, haploinsufficiency of the histone methyltransferase NSD1 causes the Sotos syndrome, that is characterized by very high stature (Kurotaki et al. [@b47]) and the gene can be inactivated epigenetically in tumors (Berdasco et al. [@b7]). PRMT5 contributes to coupling DNA methylation and chromatin organization *via* the methylation of histone H4R3, which then recruits DNMT3A. DNMT3A mediates additional regulatory loops in chromatin organization, as the HMGA1 gene itself is regulated by DNA methylation.

Heterozygous 17q11 microdeletions that encompass NF1 and RNF135 cause a subset of neurofibromatosis type 1 (Douglas et al. [@b20]). Notably, individuals with microdeletions are typically taller than individuals with NF1 mutations, consistently with the removal of a gene that negatively regulates human growth (RNF135 haploinsufficiency) (Douglas et al. [@b20]).

Prenatal environmental factors and persistence of DNA methylation changes in the adult
--------------------------------------------------------------------------------------

Epigenetic patterns in germ cells can persist into adulthood, and many imprinted genes continue to be expressed from a single parental copy. Environmental factors during pregnancy affect epigenetic marks, and in utero conditions have consequences on adult health and disease (Gluckman et al. [@b29]). This has been proven due to DNA methylation differences after exposure to prenatal famine (Tobi et al. [@b94]). Animal studies and human data on the imprinted *IGF2* locus indicated a link between prenatal nutritional and DNA methylation. Additionally, methylation of the *INSIGF*,*IL10*,*LEP*,*ABCA1, GNASAS* and *MEG3* genes was persistently modified by exposure to prenatal famine (Tobi et al. [@b94]).

In animal models manipulation of the maternal diet during pregnancy leads to a persistent shift in average DNA methylation levels of specific genes in offspring resulting in permanent changes in coat color or tail shape. Moreover, widespread dynamics of DNA methylation were shown in response to biotic stress (Dowen et al. [@b21]). Methyl donor supplementation prevents transgenerational amplification of obesity (Waterland et al. [@b100]) and maternal methyl supplements were shown to increase DNA methylation in offspring (Waterland et al. [@b99]).

Epigenetic control of height‐associated genes networks
------------------------------------------------------

Data‐bank web network meta‐analyses allowed us to connect height‐associated genes in a function‐driven web. These identified p53, c‐Myc, estrogen receptor alpha (ER*α*), HNF4A (Guerra et al. [@b33]; Trerotola et al. [@b95]) and SMADs as major hubs (Fig. [1](#fig01){ref-type="fig"}). The Hh pathway and regulatory clusters for programmed cell death/apoptosis were also identified as key control pathways, that are shared between human height and cancer.

*MYC:* Metacore analysis revealed that the c‐Myc regulates at least seven height‐associated genes (*CDK6, COIL, HMGA1, LIN28B, RBBP8, RPS20 and TRIM25/EFP*). A SNOW analysis showed that c‐Myc is a major hub of the height‐associated protein network (19 connections, betweenness 0.366). Thirty‐seven height‐associated proteins were shown to be associated in the network. The binding of c‐Myc to genomic loci is highly dependent on chromatin structure and DNA methylation (Guccione et al. [@b31]). c‐Myc modulates gene expression also by increasing methylation of the 5′ mRNA guanine or 'cap', which regulates the translation of individual mRNAs. Methylation of the cap is required for eukaryotic translation initiation factor‐4E binding and recruitment onto ribosomes for translation (Cole and Cowling [@b16]). c‐Myc regulates the cell cycle, and plays a major role in cell growth during interphase, by regulating genes required for the production of energy and metabolites. The c‐Myc network widely interacts with those driven by other major hubs. c‐Myc is repressed by transforming growth factor *β* (TGF‐*β*) through the binding of SMAD3 to the *MYC* promoter (Frederick et al. [@b28]). p53 represses c‐Myc through the induction of the tumor suppressor miR‐145 (Sachdeva et al. [@b79]). c‐Myc amply interacts also with the ER network: almost all of the acutely estrogen‐regulated genes with roles in cell growth are c‐Myc targets. Notably, estrogen‐mediated activation of rRNA and protein synthesis depends on c‐Myc (Musgrove et al. [@b63]). Equally c‐Myc dependent is the estrogen‐induced suppression of apoptosis caused by growth factor deprivation (Rodrik et al. [@b76]).

*TP53*: A major hub of height‐associated genes is *TP53*. Remarkably, at least 47 of the 87 height‐associated genes were identified as members of p53 signaling networks ([Table 1](#tbl01){ref-type="table"}), including 36 *via* direct protein--protein contacts. p53 was the most important hub (25 connections, betweenness 0.446). Metacore analysis similarly identified p53 as a hub of the height‐associated genes network. Input of p53 in the *shortest pathway* analysis indicated that p53 has a central role with a total of 125 edges pointing either in (37) or out (88) from it. Among its functions, p53 regulates the expression of target genes that modulate chromatin structure and function (Cimoli et al. [@b14]; Vousden and Lane [@b97]), cell growth, aging and apoptosis (Ambrogi et al. [@b4]; Biganzoli et al. [@b8]). p53 interacts with components of multiple different histone remodeling complexes, including CBP/EP300 (CBP/p300), GCN5, PCAF, and SETD7 modifying histones at the promoters \[(Kaneshiro et al. [@b44]) and reference therein\]. We have previously shown that p53 also controls DNA methylation levels, and that this affects genome stability (Alberti et al. [@b2]; Nasr et al. [@b65]). p53 is involved in bone remodeling, wound healing and neural tube development (Vousden and Lane [@b97]). It also performs an anti‐teratogenic function, reducing the rate of birth defects, through the induction of apoptosis of aberrant cells (Vousden and Lane [@b97]). Defects of induction of apoptosis play a role also at later stages of development \[(Rossi et al. [@b77]) and references therein\]. Female *p53*‐null mice can present neural tube‐closure defects, due to a failure to induce apoptosis of progenitor cells. This is caused by abnormal regulation of mitochondrial death pathways and results in overproduction of neural tissue. p53 has a role in the regulation of both glycolysis and oxidative phosphorylation. Low levels of p53 determine a switch from oxidative phosphorylation to glycolysis. p53 enhances oxidative phosphorylation by inducing the expression of the cytochrome c oxidase 2 subunit 1 and of the ribonucleotide reductase subunit p52R2, which are involved in the maintenance of mitochondrial DNA. p53 promotes cell survival under conditions of low or basal stress. The reduction in nutrient or energy levels causes a failure to stimulate the AKT--mTOR pathway and induces the activation of AMPK both of which lead to the induction of p53.

*ESR1*: ER*α* is a transcription factor which binds to estrogen response elements upstream of the target genes. METACORE analysis shows that ER*α* regulates at least eight height‐associated genes (*BCAS3, BMP2, BMP6, DCC, GLT25D2, PENK, RBBP8, TRIM25/EFP*). ER*α* is a major hub (16 connections, betweenness 0,376). Estrogen is candidate to be the principal hormone stimulating the pubertal growth spurt in boys as well as girls (Juul [@b42]). This action is mediated by both ER*α* and ER*β*. Polymorphisms in the *ER* gene may influence adult height in healthy male and female subjects (Schuit et al. [@b85]; Dahlgren et al. [@b19]). Consistently, men with a disruptive mutation in the ER gene have no pubertal growth spurt and continue to grow into adulthood. ER*α* blockade diminishes the secretion of endogenous growth hormone, the key hormone regulator of linear growth in childhood (Juul [@b42]). This action is mediated by SOCS‐2 (Leung et al. [@b55]). The ER*α* network widely interconnects with the p53, Hh and BMP/TGF‐*β* pathways. p53 regulates ER expression through transcriptional control of the *ER* promoter (Shirley et al. [@b87]). Of interest, DNA methyltransferase expression in the human endometrium is down‐regulated by progesterone and estrogen (Yamagata et al. [@b108]). Estrogen receptor‐negative human breast cancer cells inactivate the promoter of the *ESR1* gene by methylation of its CpG island (Ottaviano et al. [@b71]). Correspondingly, DNA methylation‐mediated gene silencing is the mechanism of ER*α* inactivation in prostatic epithelial cells (Lau et al. [@b52]).

The SNOW‐connection analysis revealed that 33 of the height‐associated proteins take part in a unique network of protein--protein contacts (Fig. [1](#fig01){ref-type="fig"}). Relevant hubs in this network are *COIL* (seven connections, betweenness 0.247) and *LYN* (seven connections, betweenness 0.146), followed by *GRB10* (six connections, betweenness 0.140) and *SF3B4* (six connections, betweenness 0.102). Coilin is a key constituent of Cajal bodies, which are responsible for the biogenesis of spliceosomal small nuclear ribonucleoprotein (snRNP) (Whittom et al. [@b106]). Cajal bodies are the initial nuclear sites for the assembly of macromolecular complexes involved in RNA processing and RNA transcription (Bogolyubov et al. [@b10]). Lyn is a Src tyrosine‐kinase family member. Signaling molecules phosphorylated by Lyn are the PI3‐kinase, STAT5 and MAP kinase. Grb10 is an adaptor protein that binds to phosphorylated tyrosines, for example, in the insulin receptor (IR) in response to insulin stimulation. Grb10 knockout mice show embryo and placenta overgrowth and a larger size at birth \[(Wang et al. [@b98]) and references therein\]. SF3b4 is a member of the spliceosome complex U2 snRNP and contributes to the recognition of the intron\'s branch point. SF3b4 also binds the BMPR‐IA serine/threonine kinase receptor and specifically inhibits BMP‐mediated SMAD1/5/8 pathway important for osteochondral cell differentiation.

Discussion
==========

Genomic loci linked to human height have been identified by genome‐wide SNP‐association analysis (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon et al. [@b104]). Corresponding GWAS in Korean (Cho et al. [@b13]) and Japanese (Okada et al. [@b69]) cohorts identified overlapping gene‐sets (Weedon and Frayling [@b102]), showing a conserved association with height in populations of both Caucasian and non‐Caucasian ancestry.

Intriguingly, although, albeit up to 90% of variation in adult height is explained by genetic factors (Silventoinen et al. [@b89]; Weedon and Frayling [@b102]), stature‐associated polymorphisms were found to only explain \<10% of height variation (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon and Frayling [@b102]; Weedon et al. [@b104]; Eichler et al. [@b24]; Lango Allen et al. [@b49]). More recent analyses have increased this predictive power (Yang et al. [@b109]). However, a large fraction of heritable height‐associated factors still escapes detection by conventional GWAS (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon and Frayling [@b102]; Weedon et al. [@b104]; Eichler et al. [@b24]; Lango Allen et al. [@b49]; Yang et al. [@b109]; Lanktree et al. [@b50]), suggesting systematic loss of information by SNP‐based analyses. Candidate for such non‐DNA sequence‐linked information is epigenetic heredity.

Our findings indicate that most of the height‐associated genes contain CpG islands and their transcriptional activity is regulated by DNA methylation. Distinct epigenetic defects have been linked to hereditary growth anomalies, indicating a broad regulatory role of DNA methylation on body growth. Further support is now provided by the association of DNA methylation/regulatory transcription to genes involved in normal body growth (Gudbjartsson et al. [@b32]; Lettre et al. [@b54]; Weedon and Frayling [@b102]; Weedon et al. [@b104]; Eichler et al. [@b24]; Lango Allen et al. [@b49]; Yang et al. [@b109]; Lanktree et al. [@b50]). The DNA methylome thus appears to contain an as yet untapped fraction of heritable traits associated with human height, that may be exploited by genome‐wide analysis of DNA methylation patterns (Liu et al. [@b58]).

DNA methylation patterns are faithfully propagated through successive cell division cycles (Alberti and Herzenberg [@b1]; Esteller [@b26]). Some of these patterns can be inherited across generations (Kaminsky et al. [@b43]; Nadeau [@b64]; Roth et al. [@b78]; Braunschweig et al. [@b11]), thus becoming true heritable traits. DNA methylation can regulate gene expression, through the inhibition/activation of gene transcription of methylated/unmethylated genes, respectively (Alberti and Herzenberg [@b1]; Esteller [@b26]), and genome stability/recombination (Alberti et al. [@b2]; Nasr et al. [@b65]).

As DNA methylation patterns are affected by environmental stimuli (El‐Osta et al. [@b25]; Guerrero‐Bosagna et al. [@b34]), this mechanism allows for a dynamic and reversible modulation of the functional content of the genome (Esteller [@b26]), in the absence of DNA sequence variation. This may help explain as yet unaccounted for multi‐generational stature trends, for example, decrease in stature in agricultural populations compared to their paleolithic predecessors (Verginelli et al. [@b96]), and the recent increase in average height (Cole [@b15]).
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